Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Crinetics Pharmaceuticals, Inc. CRNX
$22.03
-$0.08 (-0.36%)
На 18:01, 12 мая 2023
+77.03%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1201384300.00000000
-
week52high
24.58
-
week52low
15.23
-
Revenue
4737000
-
P/E TTM
0
-
Beta
0.93328900
-
EPS
-3.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 26 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 31 мар 2022 г. |
| JMP Securities | Market Outperform | 30 ноя 2021 г. | |
| Evercore ISI Group | Outperform | 23 ноя 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 08 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Betz Stephen F. | D | 64689 | 3126 | 01 февр 2023 г. |
| Betz Stephen F. | D | 67815 | 8336 | 25 янв 2023 г. |
| Betz Stephen F. | D | 76151 | 3126 | 17 янв 2023 г. |
| Betz Stephen F. | D | 79277 | 3126 | 03 янв 2023 г. |
| Betz Stephen F. | D | 82403 | 3126 | 15 дек 2022 г. |
| Betz Stephen F. | D | 84968 | 3126 | 01 дек 2022 г. |
| Knight Jeff E. | A | 5487 | 537 | 20 ноя 2022 г. |
| Krasner Alan Seth | A | 24488 | 712 | 20 ноя 2022 г. |
| Wilson Marc | A | 83546 | 482 | 20 ноя 2022 г. |
| Betz Stephen F. | D | 88094 | 3126 | 15 ноя 2022 г. |
Новостная лента
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 21:17
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.73 per share a year ago.
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
28 февр 2023 г. в 18:49
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
09 янв 2023 г. в 08:01
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data readouts which are expected in 2H 2023
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
08 сент 2022 г. в 08:00
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022, both virtually and in-person at the Lotte New York Palace Hotel.